Geron imetelstat gets FDA fast track designation for myelofibrosis

Geron’s (NASDAQ:GERN) imetelstat, a telomerase inhibitor, received FDA fast track designation for the treatment of relapsed/refractory myelofibrosis (MF).

MF is a chronic blood cancer that impairs normal blood production in the bone marrow and may affect other organs, such as the spleen and liver. There are currently no drugs approved specifically for the disease, which may develop into acute myeloid leukemia.

Geron plans to conduct an end of Phase 2 meeting with the FDA by the end of the first quarter of 2020 to discuss imetelstat’s regulatory path.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.